The development of neurotherapeutics is the next frontier in biomedical science.
The brain determines how we think, what we do, who we are. As we age, changes to our brain inevitably occur, including death of neurons, loss of synapses, brain shrinkage and cognitive impairment. In the most extreme cases, cognitive impairment is due to neurodegenerative processes, including those seen in Alzheimer's disease and other dementias. Cerecin is committed to the maintenance of brain function in health and disease.
Our Therapeutic Areas
Alzheimer's disease (AD) is an age-associated, neurodegenerative disease characterized by a progressive decline in memory and language, and, pathologically, by accumulation of senile plaques and neurofibrillary tangles in the brain. Despite significant advances in AD research, there exists a tremendous need for new AD therapies. Most developed countries will experience a dramatic demographic shift toward an older population in the next 50 years, which is anticipated to greatly increase the prevalence of AD. The rise in the number of AD patients will place a tremendous social and economic burden on the developed world.
Despite being identified over 100 years ago, the cause of Alzheimer's disease is still not well understood. Unfortunately, drug development for AD has proven to be very difficult, with few successes and many failures. Currently, only 5 drugs are approved for the treatment of AD including 4 cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine) and an N-methyl-D-aspartate (NMDA) receptor antagonist (memantine). No new compounds have been approved for AD since 2003. Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show significant effects or having unacceptable toxicity. As a result, there is a tremendous need for innovative AD therapies.
The lack of new treatments and the repeated failure of pipeline drugs have significantly impacted not only the lives of patients and associated family members, but also the economies of many developed and emerging countries. In 2013, it was calculated that the total cost for dementia care (largely AD) in the US was $215 billion. Further calculations demonstrated that the increasing prevalence of dementia, due to the aging of the US population will result in an increase of nearly 80% in total societal costs by 2040, with total care costs of approximately $511 billion. Therefore, the development of new treatments that delay onset or progression of the disease is desperately needed1. As the number of elderly surges in Asia, so does the prevalence of AD. Globally, the number of people with dementia is expected to increase to 135 million in 2050 with almost half of these cases coming from the Asia Pacific region2.